Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Two Oral Elinzanetant Formulations in Healthy Women
NCT07762287Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elinzanetant in vasomotor symptoms (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration-Time Curve Over 24 Hours After Multiple Dosing, Maximum Observed Plasma Concentration After Multiple Dosing and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07762287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762287.